Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants With Moderately Severe to Severe Hemophilia A(FVIII:C≤1%)

NCT04370054 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04370054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04370054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants With Moderately Severe to Severe Hemophilia A(FVIII:C≤1%)
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 18, 2020
Completion date
October 25, 2026
Enrollment
77 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a